Regeneron Pharmaceuticals (REGN) Could Be 14% Undervalued Following $1b Sanofi Alliance Expansion

Regeneron Pharmaceuticals (REGN) just expanded its long-running immunology alliance with Sanofi, securing a US$1b upfront payment and potential milestones up to US$7b as the pair advance four new long-acting antibody programs.

All this comes after a choppy few months for Regeneron Pharmaceuticals, with a 30-day share price return down 13.7% and a 7-day move weaker by 6.7%, while the 90-day share price return is up 12.4% and the 1-year total shareholder return is 23.2%.

Capture how the Regeneron Pharmaceuticals story fits into the wider immunology opportunity set by scanning a hand-picked 35 healthcare AI stocks that is moving on drug discovery, trial data and partnership news.

Regeneron Pharmaceuticals now appears to be a powerful immunology platform that is priced as a volatile growth story after a choppy month. The key question is whether that recent weakness leaves the valuation generous or tight.

Most Popular Narrative: 14% Undervalued

Regeneron Pharmaceuticals closed at $735.20, while the most followed narrative anchors fair value at about $850.88, implying a meaningful valuation gap that rests on how the pipeline and Sanofi alliance play out.

Regeneron Pharmaceuticals is still advancing a broad late stage pipeline in areas such as immunology, oncology, genetic medicines, and obesity. Continued readouts and regulatory decisions on these programs can add new revenue streams that support earnings growth beyond the current product portfolio.

See why 87 investors see Regeneron Pharmaceuticals as 14% undervalued.

Result: Fair Value of $850.88 (UNDERVALUED)

Still, the Regeneron Pharmaceuticals story can unravel quickly if EYLEA HD loses share to rivals like Zenkuda, or if litigation around Libtayo and fianlimab escalates into heavier financial or reputational costs.

Find out about the key risks to this Regeneron Pharmaceuticals narrative.

Next Steps

If this mix of caution and optimism around Regeneron Pharmaceuticals feels familiar, use it as a prompt to move quickly and test the numbers yourself. Then weigh those data points against the detailed breakdown of 3 key rewards.

Looking for more investment ideas beyond Regeneron Pharmaceuticals?

Do not stop your research with Regeneron Pharmaceuticals. Use this momentum to widen your watchlist and pressure test fresh ideas side by side.

• Target potential mispricing early by reviewing a curated set of 31 high quality undervalued stocks before other investors fully catch on.
• Build a steadier foundation for your portfolio by scanning a list of solid balance sheet and fundamentals (26 results) that can better handle tough conditions.
• Hunt for future leaders by checking a focused 19 high quality undiscovered gems that many investors may still be overlooking.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com